$IBRX
ImmunityBio, Inc. Stock $ibrx

$ibrx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000132611023000147 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$139.0K	$82.00K
YoY Change	90.41%	-30.51%
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$82.00K
YoY Change
Gross Profit Margin		100.0%
Selling, General & Admin	$33.11M	$31.82M
YoY Change	26.3%	64.76%
% of Gross Profit		38800.0%
Research & Development	$51.03M	$48.40M
YoY Change	-11.37%	-32.41%
% of Gross Profit		59026.83%
Depreciation & Amortization	$4.564M	$4.100M
YoY Change	-12.67%	0.0%
% of Gross Profit		5000.0%
Operating Expenses	$84.64M	$80.22M
YoY Change	0.42%	-11.77%
Operating Profit		-$80.14M
YoY Change		-11.75%
Interest Expense	-$70.44M	$35.02M
YoY Change	213.11%	108.91%
% of Operating Profit
Other Income/Expense, Net	-$77.63M	-$15.51M
YoY Change	8563.73%	-23.83%
Pretax Income	-$233.5M	-$95.64M
YoY Change	115.58%	-13.96%
Income Tax	-$40.00K	$0.00
% Of Pretax Income
Net Earnings	-$233.4M	-$95.58M
YoY Change	115.67%	-13.84%
Net Earnings / Revenue	-167907.91%	-116563.41%
Basic Earnings Per Share		-$0.19
Diluted Earnings Per Share	-$0.35	-$0.19
COMMON SHARES
Basic Shares Outstanding	667.7M shares	456.2M shares
Diluted Shares Outstanding		498.4M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$266.5M	$179.7M
YoY Change	148.6%	61.78%
Cash & Equivalents	$265.5M	$178.0M
Short-Term Investments	$1.009M	$1.700M
Other Short-Term Assets	$24.45M	$4.384M
YoY Change	555.25%	35.48%
Inventory	$0.00
Prepaid Expenses
Receivables	$0.00
Other Receivables	$2.019M	$2.325M
Total Short-Term Assets	$294.1M	$215.1M
YoY Change	109.2%	50.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$182.7M	$152.0M
YoY Change	27.16%	16.53%
Goodwill
YoY Change
Intangibles	$17.09M	$18.47M
YoY Change	-14.55%	-9.79%
Long-Term Investments	$891.0K	$817.0K
YoY Change	6.07%	0.74%
Other Assets	$2.822M	$3.427M
YoY Change	-41.93%	-33.24%
Total Long-Term Assets	$210.4M	$217.3M
YoY Change	-5.15%	3.57%
TOTAL ASSETS
Total Short-Term Assets	$294.1M	$215.1M
Total Long-Term Assets	$210.4M	$217.3M
Total Assets	$504.5M	$432.4M
YoY Change	39.21%	22.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.195M	$19.82M
YoY Change	-56.25%	-2.07%
Accrued Expenses	$46.48M	$64.87M
YoY Change	11.12%	40.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$1.475M	$2.338M
YoY Change	-69.81%	-57.33%
Total Short-Term Liabilities	$58.28M	$90.32M
YoY Change	-88.36%	27.5%
LONG-TERM LIABILITIES
Long-Term Debt	$837.0M	$673.6M
YoY Change	246.8%	1.88%
Other Long-Term Liabilities	$195.2M	$467.0K
YoY Change	42603.28%	-17.93%
Total Long-Term Liabilities	$1.032B	$467.0K
YoY Change	225743.76%	-17.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$58.28M	$90.32M
Total Long-Term Liabilities	$1.032B	$467.0K
Total Liabilities	$1.091B	$843.1M
YoY Change	34.38%	7.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.000B	-$2.700B
YoY Change	25.0%	17.39%
Common Stock	$2.375B	$2.316B
YoY Change	22.98%	25.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$587.0M	-$411.7M
YoY Change
Total Liabilities & Shareholders Equity	$504.5M	$432.4M
YoY Change	39.21%	22.52%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$233.4M	-$95.58M
YoY Change	115.67%	-13.84%
Depreciation, Depletion And Amortization	$4.564M	$4.100M
YoY Change	-12.67%	0.0%
Cash From Operating Activities	-$115.3M	-$87.41M
YoY Change	27.05%	8.44%
INVESTING ACTIVITIES
Capital Expenditures	$7.955M	$5.679M
YoY Change	-57.98%	-135.64%
Acquisitions
YoY Change
Other Investing Activities	$10.20M	-$9.960M
YoY Change	27478.38%	-167.45%
Cash From Investing Activities	$2.249M	-$15.63M
YoY Change	-111.9%	1238.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	200.5M	237.5M
YoY Change	82.41%	91.56%
NET CHANGE
Cash From Operating Activities	-115.3M	-87.41M
Cash From Investing Activities	2.249M	-15.63M
Cash From Financing Activities	200.5M	237.5M
Net Change In Cash	87.52M	134.5M
YoY Change	27334.8%	218.51%
FREE CASH FLOW
Cash From Operating Activities	-$115.3M	-$87.41M
Capital Expenditures	$7.955M	$5.679M
Free Cash Flow	-$123.2M	-$93.08M
YoY Change	12.37%	43.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	431901000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	241271000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	90922000	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	35000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	857000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	35021000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-14265000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	7517000	usd
CY2022Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1047000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20357000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-95642000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-111161000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	498375316	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	400059707	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	400059707	shares
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-95642000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-111161000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	48000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-22000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-18000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-58000	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.60
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4363000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2650000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	90324000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	500861000	usd
CY2023Q3	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	480020000	usd
CY2022Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	0	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	165289000	usd
CY2023Q3	ibrx	Convertible Notes Payable Noncurrent Fair Value Option ConvertibleNotesPayableNoncurrentFairValueOption	28281000	usd
CY2022Q4	ibrx	Convertible Notes Payable Noncurrent Fair Value Option ConvertibleNotesPayableNoncurrentFairValueOption	0	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39313000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47951000	usd
	us-gaap	Revenues Revenues	483000	usd
	us-gaap	Revenues Revenues	167000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48402000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	71612000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	180834000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	190072000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31816000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19310000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	96510000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	76493000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	80218000	usd
	us-gaap	Operating Expenses OperatingExpenses	277344000	usd
	us-gaap	Operating Expenses OperatingExpenses	266565000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-80136000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-90804000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-276861000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-266398000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	647000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	723000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	16764000	usd
	us-gaap	Interest Expense InterestExpense	97072000	usd
	us-gaap	Interest Expense InterestExpense	34953000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1255000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4456000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7549000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8553000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-31800000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	749000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2152000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	187000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15506000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-73577000	usd
	us-gaap	Profit Loss ProfitLoss	-308994000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-634000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-642000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-110938000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-349804000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-308352000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	454994192	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	454994192	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	398652562	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	398652562	shares
	us-gaap	Profit Loss ProfitLoss	-350438000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	46000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-183000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	18000	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	12000	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-119000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-245000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-130000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	820000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	0	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	820000	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	832000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-80000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	609000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-194000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-94810000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-111241000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-349829000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-309188000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-60000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-223000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-634000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-642000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94750000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-111018000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-349195000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-308546000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-449820000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10878000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	126000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	357000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-216000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-116583000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-531716000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11062000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	135000	usd
CY2023Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	60000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-138213000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-645183000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	269987000	usd
CY2023Q3	ibrx	Apic Debt Instrument Convertible Increase In Fair Value Of Embedded Conversion Feature APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature	31179000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14449000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32000	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1464000	usd
CY2023Q3	ibrx	Noncontrolling Interest Increase Decrease From Legal Settlement NoncontrollingInterestIncreaseDecreaseFromLegalSettlement	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	832000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-95642000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-410645000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-243913000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10024000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	372000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-371000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-102998000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-337556000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10175000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	15000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	257000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-94835000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-421974000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10630000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	10000	usd
CY2022Q3	ibrx	Stock Issued During Period Value Litigation Settlement StockIssuedDuringPeriodValueLitigationSettlement	10656000	usd
CY2022Q3	ibrx	Adjustments To Additional Paid In Capital Gain Loss On Extinguishment Of Debt With Related Party AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty	82858000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-80000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-111161000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-429081000	usd
	us-gaap	Profit Loss ProfitLoss	-350438000	usd
	us-gaap	Profit Loss ProfitLoss	-308994000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	36389000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30829000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	35278000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5242000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-31800000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13948000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13034000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	8988000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	8528000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4786000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4280000	usd
	ibrx	Transaction Costs Warrant Liability TransactionCostsWarrantLiability	2010000	usd
	ibrx	Transaction Costs Warrant Liability TransactionCostsWarrantLiability	0	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-851000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	162000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	749000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	16000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1318000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	681000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-459000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-127000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9463000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14420000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1385000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2138000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3599000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	7563000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	26205000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	7253000	usd
	ibrx	Increase Decrease In Due To Related Parties Current And Non Current IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent	-1299000	usd
	ibrx	Increase Decrease In Due To Related Parties Current And Non Current IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent	-1639000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2429000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2306000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-251486000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-246782000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22629000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59231000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10192000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	34293000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	102000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	33756000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	128188000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21229000	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	0	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32719000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	46191000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	258700000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	124375000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1881000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	397000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	293000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	57000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	40000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	339000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	357802000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	123673000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-265000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	123000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	73332000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76795000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104965000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	181280000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	178297000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104485000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177963000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104161000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	334000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	324000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	178297000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104485000	usd
	us-gaap	Interest Paid Net InterestPaidNet	32902000	usd
	us-gaap	Interest Paid Net InterestPaidNet	21000000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	269987000	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	usd
	ibrx	Adjustments To Additional Paid In Capital Gain Loss On Extinguishment Of Debt With Related Party AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty	0	usd
	ibrx	Adjustments To Additional Paid In Capital Gain Loss On Extinguishment Of Debt With Related Party AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty	82858000	usd
	ibrx	Issuance Of Warrants IssuanceOfWarrants	49534000	usd
	ibrx	Issuance Of Warrants IssuanceOfWarrants	0	usd
	ibrx	Apic Debt Instrument Convertible Increase In Fair Value Of Embedded Conversion Feature APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature	31179000	usd
	ibrx	Apic Debt Instrument Convertible Increase In Fair Value Of Embedded Conversion Feature APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10902000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12469000	usd
	ibrx	Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	186000	usd
	ibrx	Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	0	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	34000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-64000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	10656000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	199000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13787000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to unaudited condensed consolidated financial statements, the terms “ImmunityBio,” “the company,” “we,” “us,” and “our” refer to ImmunityBio, Inc. and its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. We strive to be a vertically-integrated immunotherapy company designing and manufacturing our products so they are more effective, accessible, more conveniently stored, and more easily administered to patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad immunotherapy and cell therapy platforms are designed to attack cancer and infectious pathogens by activating both the innate immune system—NK cells, dendritic cells, and macrophages—and the adaptive immune system—B cells and T cells—in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally infected. Our ultimate goal is to employ this approach to establish an “immunological memory” that confers long-term benefit for the patient. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, Anktiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations in combination with BCG from the FDA for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-unresponsive NMIBC with CIS</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022, we announced the submission of a BLA to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease. On May 9, 2023, the FDA delivered a CRL to us regarding the BLA filed in May 2022, indicating that the FDA had determined that it could not approve the original BLA filing in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA’s pre-license inspection of the company’s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. At the time, the FDA further provided recommendations specific to additional CMC issues and assays to be resolved. The CRL did not request new preclinical studies or Phase 3 clinical trials to evaluate safety or efficacy. The FDA requested that the company provide updated duration of response data for the efficacy population as identified by the FDA in the company’s resubmission, as well as a safety update. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. As part of our resubmission, we provided an update of the duration of response regarding the responders identified by the FDA in the efficacy population for BCG unresponsive subjects with high-risk CIS disease. On October 26, 2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA date) of April 23, 2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.</span></div>Our platforms include 13 novel therapeutic agents either in clinical trials or for which we are developing protocols. We are currently engaged in multiple active clinical trials involving our agents, some of which are being sponsored by ImmunityBio and others are investigator-led studies. Many of these trials are in Phase 2 or 3 development across several indications in liquid and solid tumors. These include bladder, pancreatic, and lung cancers, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment. In infectious diseases, our pipeline currently targets such pathogens as SARS-CoV-2 and HIV.
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2700000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-251500000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	174353379	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	73611704	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, CVR measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</span></div>
CY2022Q3	us-gaap	Depreciation Depreciation	4100000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	4100000	usd
	us-gaap	Depreciation Depreciation	12400000	usd
CY2023Q3	ibrx	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	8462000	usd
CY2022Q4	ibrx	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	11704000	usd
CY2023Q3	ibrx	Prepaid Services PrepaidServices	3813000	usd
CY2022Q4	ibrx	Prepaid Services PrepaidServices	8013000	usd
CY2023Q3	ibrx	Insurance Premium Financing Asset InsurancePremiumFinancingAsset	2338000	usd
CY2022Q4	ibrx	Insurance Premium Financing Asset InsurancePremiumFinancingAsset	1417000	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	2015000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2282000	usd
CY2023Q3	ibrx	Prepaid Software License Fees PrepaidSoftwareLicenseFees	1949000	usd
CY2022Q4	ibrx	Prepaid Software License Fees PrepaidSoftwareLicenseFees	2195000	usd
CY2023Q3	us-gaap	Supplies Supplies	0	usd
CY2022Q4	us-gaap	Supplies Supplies	2160000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4384000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3732000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22961000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	31503000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	233050000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	212911000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81050000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	69252000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	152000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143659000	usd
	us-gaap	Depreciation Depreciation	11700000	usd
CY2023Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1384000	usd
CY2023Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1384000	usd
CY2023Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	21782000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3315000	usd
CY2023Q3	ibrx	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	0	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18467000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21229000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1935000	usd
CY2022Q4	ibrx	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	681000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18613000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1390000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1390000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	22619000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1935000	usd
CY2022Q4	ibrx	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	681000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20003000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	510000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2040000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2040000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2040000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2040000	usd
CY2023Q3	ibrx	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	8413000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17083000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10644000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6685000	usd
CY2023Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	8896000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12068000	usd
CY2023Q3	ibrx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	8704000	usd
CY2022Q4	ibrx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1930000	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5969000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6040000	usd
CY2023Q3	ibrx	Accrued Preclinical And Clinical Trial Costs AccruedPreclinicalAndClinicalTrialCosts	4575000	usd
CY2022Q4	ibrx	Accrued Preclinical And Clinical Trial Costs AccruedPreclinicalAndClinicalTrialCosts	4985000	usd
CY2023Q3	ibrx	Accrued Construction Costs Current AccruedConstructionCostsCurrent	3120000	usd
CY2022Q4	ibrx	Accrued Construction Costs Current AccruedConstructionCostsCurrent	7072000	usd
CY2023Q3	ibrx	Financing Obligation Current FinancingObligationCurrent	2338000	usd
CY2022Q4	ibrx	Financing Obligation Current FinancingObligationCurrent	1417000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1103000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1628000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	64871000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41825000	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	610000	usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	253000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1486000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	2193000	usd
CY2023Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-593000	usd
CY2022Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	614000	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-851000	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	162000	usd
CY2023Q3	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	0	usd
CY2022Q3	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-10000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	0	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1513000	usd
CY2023Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	18000	usd
CY2022Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	12000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-119000	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	35000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	857000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	647000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	723000	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	19000	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	26000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	44000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	51000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	35021000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	16764000	usd
	us-gaap	Interest Expense InterestExpense	97072000	usd
	us-gaap	Interest Expense InterestExpense	34953000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11076000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	85000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10994000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	970000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	94000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	876000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	12	security
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	496000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	58000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	382000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	27000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	876000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	94000	usd
CY2023Q3	us-gaap	Marketable Securities MarketableSecurities	1700000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	2500000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-600000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	600000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-900000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	200000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	800000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35810000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45788000	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	77000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	135000	usd
CY2023Q3	ibrx	Lease Right Of Use Asset LeaseRightOfUseAsset	35887000	usd
CY2022Q4	ibrx	Lease Right Of Use Asset LeaseRightOfUseAsset	45923000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4363000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2650000	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	84000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	77000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39313000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47951000	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	64000	usd
CY2023Q3	ibrx	Lease Liability LeaseLiability	43760000	usd
CY2022Q4	ibrx	Lease Liability LeaseLiability	50742000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2023Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.117
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.117
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2768000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2841000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	8611000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	8091000	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	997000	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2086000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3026000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2086000	usd
CY2023Q3	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	21000	usd
CY2022Q3	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	56000	usd
	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	66000	usd
	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	56000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	977000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	808000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	2922000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	2924000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	4763000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	5791000	usd
	us-gaap	Lease Cost LeaseCost	14625000	usd
	us-gaap	Lease Cost LeaseCost	13157000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	7713000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	7350000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	57000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	40000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	9000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	11000	usd
	ibrx	Operating Lease Payments Related To Options To Extend Lease Terms OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms	11500000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1727000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	22000	usd
CY2023Q3	ibrx	Lease Liability To Be Paid Remainder Of Fiscal Year LeaseLiabilityToBePaidRemainderOfFiscalYear	1749000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10199000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	66000	usd
CY2023Q3	ibrx	Lease Liability To Be Paid Year One LeaseLiabilityToBePaidYearOne	10265000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10231000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2023Q3	ibrx	Lease Liability To Be Paid Year Two LeaseLiabilityToBePaidYearTwo	10231000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8334000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q3	ibrx	Lease Liability To Be Paid Year Three LeaseLiabilityToBePaidYearThree	8334000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7552000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q3	ibrx	Lease Liability To Be Paid Year Four LeaseLiabilityToBePaidYearFour	7552000	usd
CY2023Q3	ibrx	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	23248000	usd
CY2023Q3	ibrx	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2023Q3	ibrx	Lease Liability To Be Paid After Year Four LeaseLiabilityToBePaidAfterYearFour	23248000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	61291000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	88000	usd
CY2023Q3	ibrx	Lease Liability To Be Paid LeaseLiabilityToBePaid	61379000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16945000	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	4000	usd
CY2023Q3	ibrx	Lease Liability Undiscounted Excess Interest LeaseLiabilityUndiscountedExcessInterest	16949000	usd
CY2023Q3	ibrx	Lessee Operating Lease Liability Tenant Improvement Allowance Receivable LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable	670000	usd
CY2023Q3	ibrx	Finance Lease Liability Tenant Improvement Allowance Receivable FinanceLeaseLiabilityTenantImprovementAllowanceReceivable	0	usd
CY2023Q3	ibrx	Lease Liability Tenant Improvement Allowance Receivable LeaseLiabilityTenantImprovementAllowanceReceivable	670000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	43676000	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	84000	usd
CY2023Q3	ibrx	Lease Liability LeaseLiability	43760000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9262926	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.87
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4848000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	949578	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.99
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	183236	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	167592	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.48
CY2023Q3	ibrx	Fair Value Option Changes In Fair Value Including Other Comprehensive Income Loss Gain Loss FairValueOptionChangesInFairValueIncludingOtherComprehensiveIncomeLossGainLoss	8300000	usd
	ibrx	Fair Value Option Changes In Fair Value Including Other Comprehensive Income Loss Gain Loss FairValueOptionChangesInFairValueIncludingOtherComprehensiveIncomeLossGainLoss	1600000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	800000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	209291936	shares
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.29
CY2023Q3	ibrx	Apic Debt Instrument Convertible Increase In Fair Value Of Embedded Conversion Feature APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature	31200000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14449000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10630000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36389000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30829000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14449000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10630000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36389000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30829000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9861676	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.44
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	105000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	5877381	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.53
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	105000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3445499	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001

Files In Submission

Name	View Source	Status
ibrx-20230930_lab.xml	Edgar Link	unprocessable
ibrx-20230930_pre.xml	Edgar Link	unprocessable
0001326110-23-000147-index-headers.html	Edgar Link	pending
0001326110-23-000147-index.html	Edgar Link	pending
0001326110-23-000147.txt	Edgar Link	pending
0001326110-23-000147-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ibrx-20230930.htm	Edgar Link	pending
ibrx-20230930.xsd	Edgar Link	pending
ibrx-20230930_g1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ibrx-20230930_cal.xml	Edgar Link	unprocessable
ibrx-20230930_def.xml	Edgar Link	unprocessable
ibrx-2023930x10qexhibit102.htm	Edgar Link	pending
ibrx-2023930x10qexhibit103.htm	Edgar Link	pending
ibrx-2023930x10qexhibit104.htm	Edgar Link	pending
ibrx-2023930x10qexhibit105.htm	Edgar Link	pending
ibrx-2023930x10qexhibit106.htm	Edgar Link	pending
ibrx-2023930x10qexhibit107.htm	Edgar Link	pending
ibrx-2023930x10qexhibit108.htm	Edgar Link	pending
ibrx-2023930x10qexhibit109.htm	Edgar Link	pending
ibrx-2023930x10qexhibit311.htm	Edgar Link	pending
ibrx-2023930x10qexhibit312.htm	Edgar Link	pending
ibrx-2023930x10qexhibit321.htm	Edgar Link	pending
ibrx-2023930x10qexhibit322.htm	Edgar Link	pending
ibrx-2023930x10qexhibit34.htm	Edgar Link	pending
ibrx-2023930x10qexhibit41.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
ibrx-20230930_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBRX
ImmunityBio, Inc. Stock $ibrx

2023 Q4 Form 10-Q Financial Statement

#000132611023000147 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBRX ImmunityBio, Inc. Stock $ibrx

2023 Q4 Form 10-Q Financial Statement

#000132611023000147 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBRX
ImmunityBio, Inc. Stock $ibrx